

1645  
#12

CERTIFICATE OF MAILING			
I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	April 3, 2003
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket	STAN-213	
	First Named Inventor	KOBILKA, BRIAN K.	
	Application Number	09/935,061	
	Confirmation No.	7757	
	Filing Date	August 21, 2001	
	Group Art Unit	1645	
	Examiner Name	Unassigned	
Title: "CONFORMATIONAL ASSAYS TO DETECT BINDING TO G PROTEIN-COUPLED RECEPTORS"			

RECEIVED  
APR 10 2003  
TECH CENTER 1600/2900

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-213 may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 3, 2003

By:   
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\STAN (Stanford)\213\Supp IDS Statement 2.doc

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/935,061		
		Filing Date	August 21, 2001		
		First Named Inventor	KOBILKA, BRIAN K.		
		Group Art Unit	1645		
		Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	STAN-213

RECEIVED  
 APR 10 2003  
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		---				

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
			---					

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bertin, et al. "Cellular Signaling by an Agonsit-activated receptor/Gsa Fusion Protein", <i>Proc. Natl. Acad. Sci. USA</i> , (1994) Vol. 91: 8827-8831.	
		Bond, et al. "Do Recent Operational Studies Indicate That a Single State Model Is No Longer Applicable to G Protein-Coupled Receptors?", <i>Annals of New York Acad Sci.</i> , (1997) Vol. 812: 92-97.	
		Chidiac, et al. "Agonist-induced modulation of Inverse Agonsit Efficacy at the $\beta_2$ -Adrenergic Receptor", <i>Molecular Pharmacology</i> , 50: 662-669 (1996).	
		Gether, et al. "Fluorescent Labeling of Purified $\beta_2$ Adrenergic Receptor", <i>Biochem.</i> , (1996) Vol. 35: 14040-14046.	
		Gether, et al. "Agonists induce Conformational Changes in Transmembrane Domains III and VI of the $\beta_2$ Adrenoceptor", <i>The EMBO Journal</i> Vol. 16 No.22 pgs 6737-6747 (1994).	
		Hopkinson, et al. "Non-Competitive Anatagonism of $\beta_2$ -Agonsit-Mediated Cyclic AMP Accumulation by ICI 118551 in BC3H1 Cells Endogenously Expressing Constitutively Active $\beta_2$ -Adrenoceptors", <i>British Journal of Pharmacology</i> , 131: 124-130 (2000).	
		Peter Mombaerts "Seven-Transmembrane Proteins as Odorant abd Chemosensory Receptors", <i>Science</i> Vol. 286 (1999) pgs 707-711.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	09/935,061		
		Filing Date	August 21, 2001		
		First Named Inventor	KOBILKA, BRIAN K.		
		Group Art Unit	1645		
		Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	STAN-213

<b>OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Remmers, et al. "Partial G Protein Activation by Fluorescent Guanine Nucleotide Analogs", The Journal of Biological Chemistry, (1996) Vol. 271, No. 9: pgs 4791-4797.	
		Seifert, et al. "Reconstitution of $\beta_2$ -Adrenoceptor-GTP-Binding-Protein Interaction in SF9 Cells High Coupling efficiency in a $\beta_2$ -Adrenoceptor-G <sub>sa</sub> Fusion Protein", Eur J. Biochem., 255: 369-382 (1998).	
		Phillip G. Strange "Agonism and Inverse Agonism at Dopamine D <sub>2</sub> -Like Receptors", Clinical and Experimental Pharm and Physio., 26 (Suppl) S3-S9 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.